Wire · opportunities
FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
The FDA approved mFLUSIVA, Moderna's first mRNA-based influenza vaccine, for adults 50 and older, with full approval for ages 50-64 and accelerated approval for ages 65 and older requiring confirmatory trials. This represents the first mRNA flu vaccine cleared in the US, offering a quicker production timeline and potentially better flu strain matching, with submissions under review in other major markets.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 6 Aug 2026 and 12 Aug 2026.
◆ ◆ The Wire takeaway
The flu vaccine market is entering a new era where you can leverage mRNA production speed to outpace traditional egg-based vaccines. You need to plan for faster iteration cycles and prepare for midseason vaccine adjustments that could disrupt current supply chains.
◆ Coverage
9 sources · first reported 6 Aug 2026 · latest 12 Aug 2026
◆ Related on Wire
◆ Topics